ClinicalTrials.gg
CompletedNCT05787418Updated Oct 14, 2026

HH-120 Nasal Spray for Post-exposure Prevention of SARS-CoV-2

A Phase 3 interventional study of HH-120 Nasal Spray and Placebo in COVID-19, sponsored by Huahui Health. Completed at 2 sites in China. Open to participants aged 12 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Huahui Health · Phase 3, Interventional, and Prevention

How we know

Updated Oct 14, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
918
Allocation
Randomized
Ages
12 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 472 studies in COVID-19 with a site in China — 53 open to participants now, 75 under way, 8 of them phase 3. COVID-19 · China.

Enrollment
60th of 330
918 · median 200
Started
2023
with 103 others
Phase 3
46 of 472
5 open now
Registered
391st of 472
by date

Among the 472 studies in COVID-19 with a site in China, this one is the 60th largest by enrollment of the 330 interventional ones that give a count, is one of 104 that started in 2023, is one of 46 in phase 3, and was the 391st registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

53 of the 472 studies in COVID-19 with a site in China are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 12 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 472 studies in COVID-19 with a site in China, or all of them as a file.
02

Study summary

This study will assess the efficacy of HH-120 nasal spray in participants for the post-exposure prevention of SARS-CoV-2.

Read the detailed description

During this study, participants will receive HH-120 nasal spray treatment for 7 consecutive days, the efficacy and safety of HH-120 nasal spray will be assessed throughout the study period mainly based on the incidence of symptomatic SARS-CoV-2 infection and adverse events, respectively.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Severe Acute Respiratory Syndrome Coronavirus 2
  • Coronavirus disease 2019
04

Who can participate

Ages eligible
12 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 12 to 85 years old.
  • Participants with potential exposure to index patients (with known positive result of qRT-PCR or rapid antigen test [RAT]).
  • Participants will be randomized no longer than 48 hours from the onset of the COVID-19 related symptom of the index patients.
  • Participants with a negative RAT result within 2 hours prior to randomization.
  • Fertile participants must agree to use a highly effective method of .
  • Participants being able and willing to provide prior to any study-specific procedure.

Exclusion criteria

Exclusion Criteria:

  • Those with high risk of cardiac events, or severe abnormal functions of liver, kidney, lung, brain and other organs and are deemed as unsuitable to participate in the study (except for those subjects with kidney failure but received regular dialysis, or those with liver dysfunction but stabilized after treatment evaluated by the evaluation of the investigators).
  • Those comorbid with asthma.
  • Those with a history of SARS-CoV-2 infection within 3 months prior to randomization.
  • Those who has received any nasal spray or aerosol inhalation COVID-19 vaccine within 3 months prior to randomization.
  • Those who experienced symptom of upper respiratory tract infection within 2 weeks prior to randomization, such as nasal congestion, sore throat, shortness of breath (dyspnea), cough, fatigue, fever, headache, etc.
  • Known history of allergy or reaction to any component of the study drug formulation.
  • Those who has received other treatment with anti-COVID-19 indication (within 1 month or 5 half-life period prior to randomization, whichever occurs first).
  • Participants with nasal disease that is inconvenient or intolerant of nasal spray administration.
  • Other reasons considered by the investigator to be unsuitable for the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
918 participants (actual)

Study arms

  • Experimental
    HH-120 group

    HH-120 Nasal Spray

    Drug: HH-120 Nasal Spray

  • Placebo comparator
    Control group

    Placebo

    Drug: Placebo

Interventions

  • DrugHH-120Studies of HH-120HH-120 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    HH-120 nasal spray 8 times per day for 7 consecutive days

  • DrugPlacebo

    Placebo 8 times per day for 7 consecutive days

06

What researchers measure

Primary outcomes

  1. The incidence of symptomatic SARS-CoV-2 infection

    Incidence of participants with quantitative Real-Time polymerase chain reaction (qRT-PCR) confirmed SARS-CoV-2 infection and COVID-19 related symptom

    Time frame: Up to 7 days

Secondary outcomes

  1. The incidence of SARS-CoV-2 infection

    Time frame: Up to 7 days

  2. The changes in SARS-CoV-2 viral nucleic acid load

    Time frame: Up to 7 days

  3. The change of viral load by qRT-PCR

    Time frame: Up to 7 days

  4. Incidence and severity of adverse events

    Time frame: Up to 21 days

  5. The incidence of symptomatic SARS-CoV-2 infection

    Time frame: Up to 3 days

  6. The incidence of symptomatic SARS-CoV-2 infection

    Time frame: Up to 5 days

  7. Time to onset of first COVID-19 related symptom

    Time frame: Up to 7 days

  8. Proportion of participants who progress to moderate/severe/critical type of COVID-19 or death

    Time frame: Up to 21 days

  9. The incidence of symptomatic SARS-CoV-2 infection in different subgroups

    Time frame: Up to 7 days

  10. The incidence and titer of antidrug antibody (ADA)

    Time frame: Up to 21 days

07

Study locations

2 sites
  • Beijing Ditan Hospital, Capital Medical University
    Beijing, 100000, China
  • Huashan Hospital of Fudan University
    Shanghai, 200000, China
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Mar 2024, 11 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 11 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2025 → Mar 2024 and completion Apr 2026 → Apr 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
Mar 28, 2023
StartActual
Mar 31, 2023
Primary completionActual
Mar 27, 2024was Dec 2025
CompletionActual
Apr 17, 2024was Apr 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 14, 2026
Primary completion
Dec 31, 2025→Mar 27, 2024 (actual)
Oct 14, 2026
Study completion
Apr 1, 2026→Apr 17, 2024 (actual)
Oct 14, 2026
Enrollment
1200 (estimated)→918 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Enrolling by invitation→Completed
    Primary completion Dec 31, 2025→Mar 27, 2024 (now actual)
    Study completion Apr 1, 2026→Apr 17, 2024 (now actual)
    Enrollment 1200 (estimated)→918 (actual)
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05787418
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Mar 28, 2023
Start date
Mar 31, 2023
Primary completion
Mar 27, 2024
Completion
Apr 17, 2024
Last update
Oct 14, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HH-120

Start the discussion